Our hit identification services leverage computational and experimental screening to identify and confirm active compounds against validated targets. Approaches include: CADD-based de novo design, virtual screening, and fragment-based drug discovery (FBDD); Molecular docking and dynamics simulations; Medium-throughput screening and biophysics-based hit validation; Crystallography-supported DMTA (Design–Make–Test–Analyze) cycles for hit refinement. Our integrated platform ensures faster progression from hits to leads with high-quality, reproducible data for preclinical development.
Compiled from https://www.jubilantbiosys.com
